research use only
Cat.No.S6999
| Related Targets | CXCR Nrf2 Mitophagy LRRK2 ULK FKBP Heme Oxygenase cGAS LC3 Cell wall |
|---|---|
| Other Autophagy Inhibitors | Resveratrol (trans-Resveratrol) Spautin-1 PIK-III Lys05 Trihydrochloride DC661 Autophinib Spermidine SMER28 QX77 EN6 |
|
In vitro |
DMSO
: 64 mg/mL
(200.08 mM)
Ethanol : 64 mg/mL Water : Insoluble |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 319.87 | Formula | C18H26ClN3 |
Storage (From the date of receipt) | 3 years -20°C powder |
|---|---|---|---|---|---|
| CAS No. | 54-05-7 | -- | Storage of Stock Solutions |
|
|
| Synonyms | NSC-187208, CHQ, CQ | SMILES | CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl | ||
Read more about storage stability stock solution CAS number SMILES
| Targets/IC50/Ki |
Autophagy
lysosome
TLR9
HIV-1
SARS-CoV-2
(Vero E6 cells based assay) 1.13 μM(EC50)
|
|---|---|
| In vitro |
Chloroquine is a widely used autophagy inhibitor. |
| In vivo |
The inhibition of autophagy by chloroquine potentiates the therapeutic effect of PI3K/AKT inhibitors in vitro and in vivo TNBC models, synergizing with taxane-based chemotherapy. |
References |
|
(data from https://clinicaltrials.gov, updated on 2025-09-23)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT06652113 | RECRUITING | Recurrent Pregnancy Loss; Euthyroid With Thyroid Antibodies |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2024-11-15 | |
| NCT07750067 | RECRUITING | Melanoma Metastatic; NRAS Mutation |
Sun Yat-sen University |
2026-04-01 | PHASE2 |
| NCT05842174 | RECRUITING | Hepatocellular Carcinoma |
VA Office of Research and Development |
2026-04-01 | PHASE1; PHASE2 |
| NCT05841758 | RECRUITING | Sarcoidosis, Pulmonary |
Hospices Civils de Lyon |
2024-07-30 | PHASE4 |
| NCT07061717 | NOT_YET_RECRUITING | Hormone Receptor-Positive and HER2-Negative Advanced Breast Cancer |
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University |
2025-07-01 | PHASE3 |
| NCT06408298 | RECRUITING | Resectable Localized Prostate Cancer |
Lionel.D.Lewis, MD |
2026-01-06 | EARLY_PHASE1 |
Read more about Clinical Trials
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.